Opthea to update on OPT-302 trial

Latest News

Opthea (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has announced that CEO Dr Megan Baldwin will present at the Ophthalmology Innovation Summit (OIS) in Chicago this evening.

Dr Baldwin’s presentation will be made in the “Public Company Showcase” session of the OIS (https://ois.net/oisaao-2018-agenda/) together with other public ophthalmology companies.

The presentation will include an overview of Opthea’s clinical program, including an update on its phase 1b study in Diabetic Macular Edema (DME) investigating the dose-escalation of three ascending dose level groups for OPT-302 plus Bayer's EYLEA (aflibercept) in nine patients with persistent central-involved DME. 

OPT-302 is a novel VEGF-C/D ‘Trap’ therapy for the treatment of retinal eye diseases. It is currently being investigated in phase 2b and phase 1b/2a clinical trials in wet age-related macular degeneration (wet AMD) and DME respectively.

According to Dr Baldwin, “I look forward to participating in this must-attend event and to have the opportunity to present an update on Opthea’s clinical program to a broad ophthalmology and investor audience.  Our Phase 2 programs have advanced significantly over the last 12 months and continue to build on the very encouraging safety profile and activity observed in our first-in-human Phase 1/2a trial in wet AMD patients.”

A copy of the presentation will be made available on Opthea’s website.